Phase 2 Study of Adding Certolizumab to Chemotherapy and Nivolumab Before Surgery in Patients With Stage II-III Resectable Lung Cancer

What this Trial Is About

Researchers are evaluating whether adding the drug certolizumab to standard chemotherapy and nivolumab can improve treatment outcomes for people with stage II-III lung cancers that can be surgically removed. This phase II study focuses on lung adenocarcinoma and squamous cell carcinoma to see if combining certolizumab with the usual treatment reduces cancer-related inflammation and helps shrink tumors more effectively than chemotherapy and nivolumab alone. Participants will receive a combination of platinum-based chemotherapy, nivolumab, and certolizumab before surgery. Those with lung adenocarcinoma receive cisplatin and pemetrexed, while those with squamous cell carcinoma get cisplatin and gemcitabine, both on a 21-day cycle. Certolizumab is given as a 400mg injection under the skin within one hour before chemotherapy starts on day 1 of each cycle. Some participants may receive carboplatin instead of cisplatin if not eligible for cisplatin. The study includes separate groups for adenocarcinoma and squamous cell carcinoma patients. During the study, participants will be monitored for up to two years to assess their pathological response to the treatment. Researchers will evaluate tumor shrinkage and treatment effects using various tests and scans. Participants will undergo regular health assessments to monitor safety and treatment effects. The study aims to determine how well the combined therapy works and its impact on surgical outcomes and overall disease control.

Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery